Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Gross Profit | -7.1M | 2.1% |
Cost of Revenue | 7.1M | 8.3% |
Operating expense | 23M | 1.4% |
Net Income | -22M | 0.5% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 180M | 9.6% |
Total Liabilities | 29M | 2.6% |
Total Equity | 151M | 10.9% |
Shares Outstanding | 73M | 0.1% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -17M | 25.5% |
Cash from investing | 12M | 40.1% |
Cash from financing | 56,000 | 0% |
EPS
Financial Highlights for Kezar Life Sciences in Q2 '24
Gross Profit stood at -7.1M, marking a -2.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 7.1M, a 8.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 23M, showing a -1.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -22M, showing a 0.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Kezar Life Sciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.